Michelle Janelsins watched patients shuffle through cancer treatment with a frustration that had nothing to do with the disease itself. Their minds felt foggy. Conversations scattered. Tasks that once came easily now required exhausting effort. For decades, "chemo brain"—a cognitive impairment affecting as many as 80% of chemotherapy patients—has been a quiet, accepted casualty of cancer care. But a new Phase II clinical trial, published in CANCER, a peer-reviewed journal of the American Cancer Society, suggests that two remarkably ordinary interventions might help patients reclaim their mental clarity while undergoing treatment.
The challenge is real enough. Cancer-related cognitive impairment can include trouble concentrating, memory problems, and difficulty juggling multiple tasks—side effects that ripple outward, affecting work, relationships, and quality of life. Yet for years, there was little in the toolkit to address it. That's where the University of Rochester team, led by Janelsins, decided to look closer at what science already knew: both exercise and anti-inflammatory medications can support brain health in various medical conditions. The question was whether these approaches might work specifically against chemo brain.
The researchers enrolled 86 cancer patients receiving chemotherapy who reported cognitive difficulties. For six weeks, participants were randomly assigned to four groups: home-based, low-to-moderate intensity exercise (called EXCAP, which combined walking and resistance training) plus low-dose ibuprofen; EXCAP plus placebo; ibuprofen only; or placebo alone. The design was deliberate—exercise and ibuprofen reduce inflammation through different biological pathways, so scientists wanted to test whether either, or both together, could protect cognitive function during the intensity of active treatment.
The results pointed clearly toward exercise. Patients in the EXCAP-plus-placebo group performed significantly better on tests of attention than those receiving placebo alone. The cognitive gains were noticeable enough that friends, family members, and coworkers remarked on the improvement—a meaningful measure of real-world impact. Low-dose ibuprofen also showed some benefits for attention, but the effects were less pronounced. Curiously, patients taking ibuprofen showed less improvement in short-term verbal memory than those who didn't, a finding that researchers say needs further investigation.
"We are encouraged by the findings of this trial that suggest possible benefits of both interventions for some cognitive domains," said Janelsins. "Clearly, we saw a more pronounced effect with exercise, which is notable considering the multiple health benefits of exercise for cancer survivors." The observation matters because exercise offers a gift beyond just cognitive protection—it strengthens bodies weakened by treatment and builds emotional resilience during a vulnerable time.
Janelsins and her team are careful not to overstate what a single Phase II trial can show. Larger Phase III trials will be needed to confirm the findings and to explore different durations and doses for both exercise programs and ibuprofen. What's equally important is the message to patients already in treatment: there is something you can do, something within reach, that may help you stay mentally sharp. Janelsins emphasizes that anyone experiencing cognitive problems should consult their healthcare provider before starting any intervention, but the path forward looks more open than it did before.